Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor I (IGF-I) and IGF-I receptor genes and with an increase in IGF binding protein 3

Cancer Research

Volumn 58, Issue 2, 1998, Pages 215-218

  Huynh, Hung ^a   Seyam, Raouf M ^a   Brock, Gerald B ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE REPRESSION; GROWTH INHIBITION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; ORGAN WEIGHT; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RAT; TESTOSTERONE METABOLISM;

ANIMALS; BLOTTING, NORTHERN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FINASTERIDE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; ORGAN SIZE; PROSTATE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, IGF TYPE 1; RNA, MESSENGER; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0031984805     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Walsh, P. C., Madden, J. D., Harrod, M. J., Goldstein, J. L., MacDonald, P. C., and Wilson, J. D. Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N. Engl. J. Med., 291: 944-949, 1974.
2. Imperato-McGinley, J., Guerrero, L., Gautier, T., and Peterson, R. E. Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science (Washington DC), 186: 1213-1215, 1974.
3. Wilding, G. Endocrine control of prostate cancer. Cancer Surv., 23: 43-62, 1995.
4. Murphy, W. M., Soloway, M. S., and Barrows, G. H. Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer (Phila.), 68: 821-828, 1991.
5. Ferguson, J., Zincke, H., Ellison, E., Bergstralh, E., and Bostwick, D. G. Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. Urology, 44: 91-95, 1994.
6. Aquilina, J. W., Lipsky, J. J., and Bostwick, D. G. Androgen deprivation as a strategy for prostate cancer chemoprevention. J. Natl. Cancer Inst., 89: 689-696, 1997.
7. Gormley, G. J. Chemoprevention strategies for prostate cancer: the role of 5 α-reductase inhibitors. J. Cell. Biochem. Suppl., 16H: 113-117, 1992.
8. The Finasteride Study Group. Finasteride in the treatment of benign prostatic hyperplasia. Prostate, 22: 291-299, 1993.
9. Rittmaster, R. S. Drug therapy-finasteride. N. Engl. J. Med., 330: 120-125, 1994.
10. Gormley, G. J., Stoner, E., Bruskewitz, R. C., Imperato-McGinley, J., Walsh, P. C., McConnell, J. D., Andriole, G. L., Geller, J., Bracken, B. R., Tenover, J. S., Vaughen, E. D., Pappas, F., Taylor, A., Binkowitz, B., and Ng, J. The effect of finasteride in men with benign prostatic hyperplasia. N. Engl. J. Med., 327: 1185-1191, 1992.
11. Kelloff, G. J., Boone, C. W., Malone, W. F., Steele, V. E., and Doody, L. A. Introductory remarks: development of chemopreventative agents for prostate cancer. J. Cell. Biochem. Suppl., 16H: 1-8, 1992.
12. Lamb, J. C., Levy, M. A., Johnson, R. K., and Isaacs, J. T. Response of rat and human prostatic cancers to the novel 5 α-reductase inhibitor, SK&F 105657. Prostate, 21: 15-34, 1992.
13. Bologna, M., Muzi, P., Biordi, L., Festuccia, C., and Vicentini, C. Antiandrogens and 5-α reductase inhibition of the proliferation rate in PC3 and DU145 human prostatic cancer cell lines. Curr. Ther. Res., 51: 799-813, 1992.
14. Tsukamoto, S., Akaza, H., Imada, S., Koiso, K., Shirai, T., Ideyama, Y., and Kudo, M. Chemoprevention of rat prostate carcinogenesis by use of finasteride or casodex. J. Natl. Cancer Inst., 87: 842-843, 1995.
15. Oesterling, J. E. Benign prostatic hyperplasia. Medical and minimally invasive treatment options. N. Engl. J. Med., 332: 99-109, 1995.
16. Stoner, E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology, 43: 284-294, 1994.
17. Boyle, P., Gould, A. L., and Roehrbom, C. G. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology, 48: 398-405, 1996.
18. Feigl, P., Blumenstein, B., Thompson, I., Crowley, J., Wolf, M., Kramer, B. S., Coltman, C. A., Jr., Brawley, O. W., and Ford, L. G. Design of the Prostate Cancer Prevention Trial. (PCPT). Controlled Clin. Trials, 16: 150-163, 1995.
19. Guenette, R. S., and Tenniswood, M. The role of growth factors in the suppression of active cell death in the prostate: a hypothesis. Biochem. Cell Biol., 72: 553-559, 1994.
20. Cohen, P., Peehl, D. M., Lamson, G., and Rosenfeld, R. G. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J. Clin. Endocrinol. Metab., 73: 401-407, 1991.
21. Fleshner, N. E., and Trachtenberg, J. Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects. J. Urol., 154: 1642-1646, 1995.
22. Iwamura, M., Sluss, P. M., Cassmento, J. B., Cockett, A. T. K., Casamento, J. B., and Cockett, A. T. Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate, 22: 243-252, 1993.
23. Drivdahl, R. H., Loop, S. M., Andress, D. L., and Ostenson, R. C. IGF-binding proteins in human prostate tumor cells: expression and regulation by 1,25-dihydroxyvitamin D3. Prostate, 26: 72-79, 1995.
24. Jones, J. I., and Clemmons, D. R. Insulin-like growth factors and their binding proteins: biological actions. Endocrinol. Rev., 16: 3-34, 1995.
25. Yallampalli, C., Rajaraman, S., and Nagamani, M. Insulin-like growth factor binding proteins in the rat uterus and their regulation by oestradiol and growth hormone. J. Reprod. Fertil., 97: 501-505, 1993.
26. Oh, Y. M., Nagalla, S. R., Yamanaka, Y., Kim, H. S., Wilson, E., and Rosenfeld, R. G. Synthesis and characterization of insulin-like growth factor binding protein (IGFBP)-7. Recombinant human MAC25 protein specifically binds IGF-I and II. J. Biol. Chem., 271: 30322-30325, 1996.
27. Elgin, R. G., Busby, W. H., and Clemmons, D. R. An insulin-like growth factor (IGF) binding protein enhances the biological response to IGF-I. Proc. Natl. Acad. Sci. USA, 84: 3254-3258, 1987.
28. Rutanen, E. M., Pekonen, F., and Makinen, T. Soluble 34K binding protein inhibits the binding of insulin-like growth factor I to its cell receptors in human secretory phase endometrium: evidence for autocrine/paracrine regulation of growth factor action. J. Clin. Endocrinol. Metab., 66: 173-180, 1988.
29. Kiefer, M. C., Schmid, C., Waldvogel, M., Schlapfer, I., Futo, E., Masiarz, F. R., Green, K., Barr, P. J., and Zapf, J. Characterization of recombinant human insulin-like growth factor binding proteins 4, 5, and 6 produced in yeast. J. Biol. Chem., 267: 12692-12699, 1992.
30. Oh, Y., Muller, H. L., Ng, L., and Rosenfeld, R. G. Transforming growth factor-β-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J. Biol. Chem., 270: 13589-13592, 1995.
31. Huynh, H. T., Yang, X., and Pollak, M. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J. Biol. Chem., 271: 1016-1021, 1996.
32. Huynh, H. T., Yang, X., and Pollak, M. A role for insulin-like growth factor binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780. Cell Growth Differ., 7: 1501-1506, 1996.
33. Cohen, P., Peehl, D. M., and Rosenfeld, R. G. The IGF axis in the prostate. Horm. Metab. Res., 26: 81-84, 1994.
34. Angelloz-Nicoud, P., and Binoux, M. Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3). Endocrinology, 136: 5485-5492, 1995.
35. Nickerson, T., Pollak, M., and Huynh, H. Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2, 3, 4 and 5. Endocrinology, in press, 1998.
36. Rajah, R., Valentinis, B., and Cohen, P. Insulin-like growth factor binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53-and IGF-independent mechanism. J. Biol. Chem., 272: 12181-12188, 1997.
37. Oh, Y., Muller, H. L., Lamson, G., and Rosenfeld, R. G. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. J. Biol. Chem., 268: 14964-14971, 1993.
38. Huynh, H. T., Tetenes, E., Wallace, L., and Pollak, M. In vivo inhibition of insulin-like growth factor-I gene expression by tamoxifen. Cancer Res., 53: 1727-1730, 1993.
39. Pollak, M., Polychronakos, C., Yousefi, S., and Richard, M. Characterization of insulin-like growth factor (IGF-I) receptors of human breast cancer cells. Biochem. Biophys Res. Commun., 154: 326-331, 1988.
40. Norman, R. W., Coakes, K. E., Wright, A. S., and Rittmaster, R. S. Androgen metabolism in men receiving finasteride before prostatectomy. J. Urol., 150: 1736-1739, 1993.
41. Resnicoff, M., Abraham, D., Yutanawiboonchai, W., Rotman, H. L., Kajstura, J., Rubin, R., Zoltick, P., and Baserga, R. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res., 55: 2463-2469, 1995.
42. Baserga, R. The insulin-like growth factor 1 receptor: a key to tumor growth? Cancer Res., 55: 249-252, 1995.
43. Valentinis, B., Bhala, A., DeAngelis, T., Baserga, R., and Cohen, P. The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Mol. Endocrinol., 9: 361-367, 1995.
44. 3. Endocrinology, 13: 20-26, 1995.
45. Martin, J. L., Ballesteros, M., and Baxter, R. C. Insulin-like growth factor-I (IGF-I) and transforming growth factor-β1 release IGF-binding protein-3 from human fibroblasts by different mechanisms. Endocrinology, 131: 1703-1710, 1992.
46. Murphy, L. J., Bell, G. I., Duckworth, M. L., and Friesen, H. G. Identification, characterization, and regulation of a rat complementary deoxyribonucleic acid which encodes insulin-like growth factor-I. Endocrinology, 121: 684-691, 1987.
47. Shimasaki, S., and Ling, N. Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5 and -6). Prog. Growth Factor Res., 3: 243-266, 1991.